# FDA Grants Accelerated Approval to Atacicept (Trutakna) for IgA Nephropathy

> fda · REPORTED · 2026-07-07

The FDA on July 7, 2026, granted accelerated approval to Vera Therapeutics' atacicept-vymj, marketed as Trutakna, for adults with primary immunoglobulin A nephropathy at risk of disease progression, based on a 42% reduction in proteinuria versus placebo at 9 months. It is the first FDA-approved medicine to target two proteins involved in the survival and maturation of certain immune cells causing the disease.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biotechnology company developing treatments for serious immunological diseases, with atacicept representing its lead asset targeting the APRIL and BAFF cytokines implicated in IgA nephropathy pathogenesis.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://www.pharmtech.com/view/fda-activity-round-up-july-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.